Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY Trials
SEATTLE, May 14, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, today announced that it will host a virtual key opinion leader event focused on the evolving clinical and translational data supporting the development of (Z)-endoxifen, the Company's investigational selective estrogen receptor modulator/degrader, or SERM/D, as a potential next-generation endocrine therapy backbone across multiple estrogen receptor ("ER") -positive breast cancer settings.
The event will feature internationally recognized surgical oncologist and breast cancer expert Dr. Laura Esserman. Dr. Esserman serves as Director of the University of California San Francisco Breast Care Center and is the founder and principal investigator of the I-SPY Trials, an innovative platform designed to accelerate the development of personalized breast cancer therapies.
The discussion is expected to address several topics of interest to clinicians, investors, and potential strategic partners, including:
- Recent data from the I-SPY2 Endocrine Optimization Pilot study evaluating (Z)-endoxifen as monotherapy in newly diagnosed ER-positive breast cancer patients
- Translational biomarker data, including Ki-67 reduction, MRI functional tumor volume changes, and circulating tumor DNA dynamics
- Data supporting (Z)-endoxifen activity across clinically relevant ESR1 mutations, including Y537N, Y537S, and D538G
- The rationale for (Z)-endoxifen as a potential next-generation endocrine therapy backbone
- Combination strategies, including CDK4/6 inhibitor combinations
- Development opportunities in premenopausal breast cancer and endocrine therapy optimization